Immunological platelet transfusion refractoriness: current insights from mechanisms to therapeutics

References

• McFarland J, Menitove J, Kagen L, Braine H, Kickler T, Ness P, Fuller A, Slichter S, Gernsheimer T, Townsend-McCall D. et al. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med. 1997;337(26):1861–9.
   PubMed Web of Science ®Google Scholar
• Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Haematol. 2008;142(3):348–360. doi:10.1111/j.1365-2141.2008.07189.x.
   PubMed Web of Science ®Google Scholar
• Toor AA, Choo SY, Little JA. Bleeding risk and platelet transfusion refractoriness in patients with acute myelogenous leukemia who undergo autologous stem cell transplantation. Bone Marrow Transplant. 2000;26(3):315–320. doi:10.1038/sj.bmt.1702490.
   PubMed Web of Science ®Google Scholar
• Kerkhoffs JL, Eikenboom JC, van de Watering LM, van Wordragen-Vlaswinkel RJ, Wijermans PW, Brand A. The clinical impact of platelet refractoriness: correlation with bleeding and survival. Transfusion. 2008;48(9):1959–65. doi:10.1111/j.1537-2995.2008.01799.x.
   PubMed Web of Science ®Google Scholar
• Davis KB, Slichter SJ, Corash L. Corrected count increment and percent platelet recovery as measures of posttransfusion platelet response: problems and a solution. Transfusion. 1999;39(6):586–592. doi:10.1046/j.1537-2995.1999.39060586.x.
   PubMed Web of Science ®Google Scholar
• Cohn CS. Platelet transfusion refractoriness: how do I diagnose and manage? Hematol Am Soc Hematol Educ Program. 2020;2020(1):527–532. doi:10.1182/hematology.2020000137.
   PubMedGoogle Scholar
• Legler TJ, Fischer I, Dittmann J, Simson G, Lynen R, Humpe A, Riggert J, Schleyer E, Kern W, Hiddemann W. et al. Frequency and causes of refractoriness in multiply transfused patients. Ann Hematol. 1997;74(4):185–189. doi:10.1007/s002770050280.
   PubMed Web of Science ®Google Scholar
• Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ, Kickler T, Lee E, McFarland J, McCullough J. et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood. 2005;105(10):4106–14. doi:10.1182/blood-2003-08-2724.
   PubMed Web of Science ®Google Scholar
• Curtis BR, McFarland JG. Human platelet antigens - 2013. Vox Sang. 2014;106(2):93–102. doi:10.1111/vox.12085.
   PubMed Web of Science ®Google Scholar
• Schmidt AE, Refaai MA, Coppage M. HLA-Mediated platelet refractoriness. Am J Clin Pathol. 2019;151(4):353–363. doi:10.1093/ajcp/aqy121.
   PubMed Web of Science ®Google Scholar
• Rijkers M, Saris A, Heidt S, Mulder A, Porcelijn L, Claas FHJ, Bierings R, Leebeek FWG, Jansen AJG, Vidarsson G. et al. A subset of anti-HLA antibodies induces FcγRIIa-dependent platelet activation. Haematologica. 2018;103(10):1741–1752. doi:10.3324/haematol.2018.189365.
   PubMed Web of Science ®Google Scholar
• Rijkers M, Schmidt D, Lu N, Kramer CSM, Heidt S, Mulder A, Porcelijn L, Claas FHJ, Leebeek FWG, Jansen AJG. et al. Anti-HLA antibodies with complementary and synergistic interaction geometries promote classical complement activation on platelets. Haematologica. 2019;104(2):403–416. doi:10.3324/haematol.2018.201665.
   PubMed Web of Science ®Google Scholar
• Rubinstein E, Kouns WC, Jennings LK, Boucheix C, Carroll RC. Interaction of 2 GPIIb iiia monoclonal-antibodies with platelet fc receptor (Fc-gamma-RII). Br J Haematol. 1991;78(1):80–6. doi:10.1111/j.1365-2141.1991.tb04386.x.
   PubMed Web of Science ®Google Scholar
• Sullam PM, Hyun WC, Szollosi J, Dong JF, Foss WM, Lopez JA. Physical proximity and functional interplay of the glycoprotein Ib-IX-V complex and the Fc receptor Fc gamma RIIA on the platelet plasma membrane. J Biol Chem. 1998;273(9):5331–6. doi:10.1074/jbc.273.9.5331.
   PubMed Web of Science ®Google Scholar
• Van Osch TLJ, Oosterhoff JJ, Bentlage AEH, Nouta J, Koeleman CAM, Geerdes DM, Mok JY, Heidt S, Mulder A, Van Esch WJE. et al. Fc galactosylation of anti-platelet hIgG1 alloantibodies enhance complement activation on platelets. Haematologica. 2022;107:2432–44. doi:10.3324/haematol.2021.280493.
   PubMed Web of Science ®Google Scholar
• Seielstad M, Page GP, Gaddis N, Lanteri M, Lee T-H, Kakaiya R, Barcellos LF, Criswell LA, Triulzi D, Norris PJ. et al. Genomewide association study of HLA alloimmunization in previously pregnant blood donors. Transfusion. 2018;58(2):402–412. doi:10.1111/trf.14402.
   PubMed Web of Science ®Google Scholar
• Avenia Silvestre AP, Valentini Zacarias JM, Soares Guelsin GA, Laguila Visentainer JE, Sell AM. Genetic polymorphisms of human platelet antigens in Euro-African and Japanese descendants from Parana, Southern Brazil. Platelets. 2017;28(6):607–610. doi:10.1080/09537104.2016.1257785.
   PubMed Web of Science ®Google Scholar
• Neffati A, Sellami MH, Bellali H, Kâabi H, Chaabene M, Hmida S. Polymorphism of human platelet antigens in Tunisian population: clinical and anthropological interests. Transfus Clin Biol. 2019;26(4):266–72. doi:10.1016/j.tracli.2019.02.001.
   PubMed Web of Science ®Google Scholar
• Sayeh E, Sterling K, Speck E, Freedman J, Semple JW. IgG antiplatelet immunity is dependent on an early innate natural killer cell-derived interferon-gamma response that is regulated by CD8+ T cells. Blood. 2004;103(7):2705–9. doi:10.1182/blood-2003-10-3552.
   PubMed Web of Science ®Google Scholar
• Arthur CM, Patel SR, Sullivan HC, Winkler AM, Tormey CA, Hendrickson JE, Stowell SR. CD8+ T cells mediate antibody-independent platelet clearance in mice. Blood. 2016;127(14):1823–1827. doi:10.1182/blood-2015-10-673426.
   PubMed Web of Science ®Google Scholar
• Qiu J, Liu X, Li X, Zhang X, Han P, Zhou H, Shao L, Hou Y, Min Y, Kong Z. et al. CD8(+) T cells induce platelet clearance in the liver via platelet desialylation in immune thrombocytopenia. Sci Rep. 2016;6:27445. doi:10.1038/srep27445.
   PubMed Web of Science ®Google Scholar
• Vrbensky JR, Nazy I, Clare R, Larche M, Arnold DM. T cell-mediated autoimmunity in immune thrombocytopenia. Eur J Haematol. 2022;108(1):18–27. doi:10.1111/ejh.13705.
   PubMed Web of Science ®Google Scholar
• Wool GD, Brown N. Chapter 8 - Alloantibodies and platelets. In: Maitta RW, editor. Immunologic concepts in transfusion medicine. Elsevier; 2020. p. 117–48. doi:10.1016/B978-0-323-67509-3.00008-1.
   Google Scholar
• Boshkov LK, Kelton JG, Halloran PF. HLA-DR expression by platelets in acute idiopathic thrombocytopenic purpura. Br J Haematol. 1992;81(4):552–557. doi:10.1111/j.1365-2141.1992.tb02991.x.
   PubMed Web of Science ®Google Scholar
• Semple JW, Milev Y, Cosgrave D, Mody M, Hornstein A, Blanchette V, Freedman J. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood. 1996;87(10):4245–4254. doi:10.1182/blood.V87.10.4245.bloodjournal87104245.
   PubMed Web of Science ®Google Scholar
• Blandin L, Douge A, Fayard A, Bay JO, Berlie G, Pereira B, Lemal R, Rouzaire P. Platelet transfusion refractoriness and anti-HLA immunization. Transfusion. 2021;61(6):1700–1704. doi:10.1111/trf.16358.
   PubMed Web of Science ®Google Scholar
• Poston JN, Jash A, Hannan LM, Hay AM, Usaneerungrueng C, Howie HL, Kapp LM, Zimring JC. In utero exposure to alloantigens primes alloimmunization to platelet transfusion in mice. Transfusion. 2021;61(3):687–691. doi:10.1111/trf.16224.
   PubMed Web of Science ®Google Scholar
• Bang KWA, Speck ER, Blanchette VS, Freedman J, Semple JW. Unique processing pathways within recipient antigen-presenting cells determine IgG immunity against donor platelet MHC antigens. Blood. 2000;95(5):1735–1742. doi:10.1182/blood.V95.5.1735.005k47_1735_1742.
   PubMed Web of Science ®Google Scholar
• Bang A, Speck ER, Blanchette VS, Freedman J, Semple JW. Recipient humoral immunity against leukoreduced allogeneic platelets is suppressed by aminoguanidine, a selective inhibitor of inducible nitric oxide synthase. Blood. 1996;88(8):2959–2966. doi:10.1182/blood.V88.8.2959.bloodjournal8882959.
   PubMed Web of Science ®Google Scholar
• Bang KW, Speck ER, Blanchette VS, Freedman J, Semple JW. Unique processing pathways within recipient antigen-presenting cells determine IgG immunity against donor platelet MHC antigens. Blood. 2000;95(5):1735–1742. doi:10.1182/blood.V95.5.1735.005k47_1735_1742.
   PubMed Web of Science ®Google Scholar
• Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391(6667):591–594. doi:10.1038/35393.
   PubMed Web of Science ®Google Scholar
• Elzey BD, Ratliff TL, Sowa JM, Crist SA. Platelet CD40L at the interface of adaptive immunity. Thromb Res. 2011;127(3):180–183. doi:10.1016/j.thromres.2010.10.011.
   PubMed Web of Science ®Google Scholar
• Sprague DL, Elzey BD, Crist SA, Waldschmidt TJ, Jensen RJ, Ratliff TL. Platelet-mediated modulation of adaptive immunity: unique delivery of CD154 signal by platelet-derived membrane vesicles. Blood. 2008;111(10):5028–5036. doi:10.1182/blood-2007-06-097410.
   PubMed Web of Science ®Google Scholar
• Polgár J, Eichler P, Greinacher A, Clemetson KJ. Adenosine diphosphate (ADP) and ADP receptor play a major role in platelet activation/aggregation induced by sera from heparin-induced thrombocytopenia patients. Blood. 1998;91(2):549–554. doi:10.1182/blood.V91.2.549.
   PubMed Web of Science ®Google Scholar
• Gratacap MP, Herault JP, Viala C, Ragab A, Savi P, Herbert JM, Chap H, Plantavid M, Payrastre B. Fc gamma RIIA requires a Gi-dependent pathway for an efficient stimulation of phosphoinositide 3-kinase, calcium mobilization, and platelet aggregation. Blood. 2000;96(10):3439–46. doi:10.1182/blood.V96.10.3439.
   PubMed Web of Science ®Google Scholar
• McKenzie SE. Humanized mouse models of FcR clearance in immune platelet disorders. Blood Rev. 2002;16(1):3–5. doi:10.1054/blre.2001.0170.
   PubMed Web of Science ®Google Scholar
• Marini I, Zlamal J, Faul C, Holzer U, Hammer S, Pelzl L, Bethge W, Althaus K, Bakchoul T. Autoantibody-mediated desialylation impairs human thrombopoiesis and platelet lifespan. Haematologica. 2021;106(1):196–207. doi:10.3324/haematol.2019.236117.
   PubMed Web of Science ®Google Scholar
• Patel P, Michael JV, Naik UP, McKenzie SE. Platelet FcgammaRIIA in immunity and thrombosis: adaptive immunothrombosis. J Thromb Haemost. 2021;19(5):1149–60. doi:10.1111/jth.15265.
   PubMed Web of Science ®Google Scholar
• Arman M, Krauel K. Human platelet IgG Fc receptor FcgammaRIIA in immunity and thrombosis. J Thromb Haemost. 2015;13(6):893–908. doi:10.1111/jth.12905.
   PubMed Web of Science ®Google Scholar
• Maxwell KF, Powell MS, Hulett MD, Barton PA, McKenzie IFC, Garrett TPJ, Hogarth PM. Crystal structure of the human leukocyte Fc receptor, Fc gamma RIIa. Nat Struct Biol. 1999;6(5):437–42. doi:10.1038/8241.
   PubMedGoogle Scholar
• Chen J, Dong JF, Sun C, Bergeron A, McBride L, Pillai M, Barnard MR, Salmon J, Michelson AD, Bray PF. Platelet FcgammaRIIA His131Arg polymorphism and platelet function: antibodies to platelet-bound fibrinogen induce platelet activation. J Thromb Haemost. 2003;1(2):355–62. doi:10.1046/j.1538-7836.2003.00054.x.
   PubMed Web of Science ®Google Scholar
• Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, Daeron M. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood. 2009;113(16):3716–25. doi:10.1182/blood-2008-09-179754.
   PubMed Web of Science ®Google Scholar
• Grozovsky R, Hoffmeister KM, Falet H. Novel clearance mechanisms of platelets. Curr Opin Hematol. 2010;17(6):585–589. doi:10.1097/MOH.0b013e32833e7561.
   PubMed Web of Science ®Google Scholar
• Saris A, Pavenski K. Human Leukocyte Antigen Alloimmunization and Alloimmune Platelet Refractoriness. Transfus Med Rev. 2020;34(4):250–257. doi:10.1016/j.tmrv.2020.09.010.
   PubMed Web of Science ®Google Scholar
• Beligaswatte A, Tsiopelas E, Humphreys I, Bennett G, Robinson K, Davis K, Bardy P. The mean fluorescence intensities of anti-HLA antibodies detected using micro-bead flow cytometry predict the risk of platelet transfusion refractoriness. Br J Haematol. 2013;162(3):409–412. doi:10.1111/bjh.12369.
   PubMed Web of Science ®Google Scholar
• Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5. doi:10.3389/fimmu.2014.00520.
   PubMed Web of Science ®Google Scholar
• Saris A, Tomson B, Brand A, Mulder A, Claas FH, Lorinser J, Scharenberg J, van Ham SM, ten Brinke A, Zwaginga JJ. et al. Platelets from donors with consistently low HLA-B8,-B12, or-B35 expression do not undergo antibody-mediated internalization. Blood. 2018;131(1):144–152. doi:10.1182/blood-2017-07-799270.
   PubMed Web of Science ®Google Scholar
• Li J, van der Wal DE, Zhu G, Xu M, Yougbare I, Ma L, Vadasz B, Carrim N, Grozovsky R, Ruan M. et al. Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia. Nat Commun. 2015;6(1):7737. doi:10.1038/ncomms8737.
   PubMedGoogle Scholar
• Li J, Sullivan JA, Ni H. Pathophysiology of immune thrombocytopenia. Curr Opin Hematol. 2018;25(5):373–381. doi:10.1097/MOH.0000000000000447.
   PubMed Web of Science ®Google Scholar
• Xu X, Liu Y, Hong X, Chen S, Ma K, Lan X, Ying Y, He J, Zhu F, Lv H. Variants of CD36 gene and their association with CD36 protein expression in platelets. Blood Transfus = Trasfusione del sangue. 2014;12(4):557–64. doi:10.2450/2014.0209-13.
   PubMed Web of Science ®Google Scholar
• Phuangtham R, Santoso S, Leelayuwat C, Komvilaisak P, Ding H, Romphruk AV. Frequency of CD36 deficiency in thais analyzed by quantification of CD36 on cell surfaces and in plasma. Transfusion. 2020;60(4):847–854. doi:10.1111/trf.15737.
   PubMed Web of Science ®Google Scholar
• Liu J, Shao Y, Ding H, Deng J, Xu X, Wang J, Xia W, Santoso S, Ye X, Fu Y. Distribution of CD36 deficiency in different Chinese ethnic groups. Hum Immunol. 2020;81(7):366–371. doi:10.1016/j.humimm.2020.05.004.
   PubMed Web of Science ®Google Scholar
• Flesch BK, Scherer V, Opitz A, Ochmann O, Janson A, Steitz M, Zeiler T. Platelet CD36 deficiency is present in 2.6% of Arabian individuals and can cause NAIT and platelet refractoriness. Transfusion. 2021;61(6):1932–1942. doi:10.1111/trf.16398.
   PubMed Web of Science ®Google Scholar
• Schipper RF, Schreuder GMT, D’Amaro J, Oudshoorn M. HLA gene and haplotype frequencies in Dutch blood donors. Tissue Antigens. 1996;48(5):562–574. doi:10.1111/j.1399-0039.1996.tb02670.x.
   PubMedGoogle Scholar
• Saito S, Ota S, Seshimo H, Yamazaki Y, Nomura S, Ito T, Miki J, Ota M, Fulushima H, Maeda H. Platelet transfusion refractoriness caused by a mismatch in HLA-C antigens. Transfusion. 2002;42(3):302–8. doi:10.1046/j.1537-2995.2002.00051.x.
   PubMed Web of Science ®Google Scholar
• Pappalardo PA, Secord AR, Quitevis P, Haimowitz MD, Goldfinger D. Platelet transfusion refractoriness associated with HPA-1a (Pl(A1)) alloantibody without coexistent HLA antibodies successfully treated with antigen-negative platelet transfusions. Transfusion. 2001;41(8):984–7. doi:10.1046/j.1537-2995.2001.41080984.x.
   PubMed Web of Science ®Google Scholar
• Marsh JC, Stanworth SJ, Pankhurst LA, Kallon D, Gilbertson AZ, Pigden C, Deary AJ, Mora AS, Brown J, Laing ES. et al. An epitope-based approach of HLA-matched platelets for transfusion: a noninferiority crossover randomized trial. Blood. 2021;137(3):310–322. doi:10.1182/blood.2020007199.
   PubMed Web of Science ®Google Scholar
• Duquesnoy RJ. Structural epitope matching for HLA-alloimmunized thrombocytopenic patients: a new strategy to provide more effective platelet transfusion support? Transfusion. 2008;48(2):221–227. doi:10.1111/j.1537-2995.2007.01516.x.
   PubMed Web of Science ®Google Scholar
• Karlstrom C, Linjama T, Edgren G, Lauronen J, Wikman A, Hoglund P. HLA-selected platelets for platelet refractory patients with HLA antibodies: a single-center experience. Transfusion. 2019;59(3):945–952. doi:10.1111/trf.15108.
   PubMed Web of Science ®Google Scholar
• Blumberg N, Masel D, Mayer T, Horan P, Heal J. Removal of HLA-a,b antigens from platelets. Blood. 1984;63(2):448–50. doi:10.1182/blood.V63.2.448.448.
   PubMed Web of Science ®Google Scholar
• Shanwell A, Sallander S, Olsson I, Gulliksson H, Pedajas I, Lerner R. An alloimmunized, thrombocytopenic patient successfully transfused with acid-treated, random-donor platelets. Br J Haematol. 1991;79(3):462–5. doi:10.1111/j.1365-2141.1991.tb08056.x.
   PubMed Web of Science ®Google Scholar
• Shanwell A. Treatment of alloimmunized, thrombocytopenic patient with acid-treated random donor platelets - reply. Br J Haematol. 1992;81(1):135–135. doi:10.1111/j.1365-2141.1992.tb08192.x.
   PubMed Web of Science ®Google Scholar
• Castro E, Muncunill J, Barea L, Gonzalez R, Fernandez-Villalta MJ. Acid elution of platelets HLA-class I antigens in the treatment of a refractory patient. Br J Haematol. 1998;100(1):245–6. doi:10.1046/j.1365-2141.1998.00577.x.
   PubMed Web of Science ®Google Scholar
• Novotny VMJ, Huizinga TWJ, vanDoorn R, Briet E, Brand A. HLA class I-eluted platelets as an alternative to HLA-matched platelets. Transfusion. 1996;36(5):438–444. doi:10.1046/j.1537-2995.1996.36596282588.x.
   PubMed Web of Science ®Google Scholar
• Bertolini F, Porretti L, Corsini C, Rebulla P, Sirchia G. Platelet quality and reduction of HLA expression in acid-treated platelet concentrates. Br J Haematol. 1993;83(3):525–527. doi:10.1111/j.1365-2141.1993.tb04684.x.
   PubMed Web of Science ®Google Scholar
• Murphy MF, Metcalfe P, Caples R, Waters AH. Function of acid-treated platelets for transfusion. Br J Haematol. 1992;82(1):176–178. doi:10.1111/j.1365-2141.1992.tb04615.x.
   PubMed Web of Science ®Google Scholar
• Mirlashari MR, Vetlesen A, Nissen-Meyer LSH, Stensland ME, Singh SK, Nyman TA, Hetland G. Proteomic study of apheresis platelets made HLA class I deficient for transfusion of refractory patients. Proteomics Clin Appl. 2021;15(6):e2100022. doi:10.1002/prca.202100022.
   PubMed Web of Science ®Google Scholar
• Meinke S, Sandgren P, Mörtberg A, Karlström C, Kadri N, Wikman A, Höglund P. Platelets made HLA deficient by acid treatment aggregate normally and escape destruction by complement and phagocytes in the presence of HLA antibodies. Transfusion. 2016;56(2):370–382; quiz 369. doi:10.1111/trf.13350.
   PubMed Web of Science ®Google Scholar
• Mirlashari MR, Vetlesen A, Nissen-Meyer LSH, Naper C, Tjonnfjord GE, Njerve IU, Ezligini F, Landmark BF, Meinke S, Sandgren P. et al. HLA class I depletion by citric acid, and irradiation of apheresis platelets for transfusion of refractory patients. Transfusion. 2021;61(4):1222–1234. doi:10.1111/trf.16282.
   PubMed Web of Science ®Google Scholar
• Feng Q, Shabrani N, Thon JN, Huo HG, Thiel A, Machlus KR, Kim K, Brooks J, Li F, Luo CM. et al. Scalable generation of universal platelets from human induced pluripotent stem cells. Stem Cell Rep. 2014;3(5):817–831. doi:10.1016/j.stemcr.2014.09.010.
   PubMed Web of Science ®Google Scholar
• Figueiredo C, Goudeva L, Horn PA, Eiz-Vesper B, Blasczyk R, Seltsam A. Generation of HLA-deficient platelets from hematopoietic progenitor cells. Transfusion. 2010;50(8):1690–1701. doi:10.1111/j.1537-2995.2010.02644.x.
   PubMed Web of Science ®Google Scholar
• Matsunaga T, Tanaka I, Kobune M, Kawano Y, Tanaka M, Kuribayashi K, Iyama S, Sato T, Sato Y, Takimoto R. et al. Ex vivo large-scale generation of human platelets from cord blood CD34(+) cells. Stem Cells. 2006;24(12):2877–87. doi:10.1634/stemcells.2006-0309.
   PubMed Web of Science ®Google Scholar
• Takayama N, Nishimura S, Nakamura S, Shimizu T, Ohnishi R, Endo H, Yamaguchi T, Otsu M, Nishimura K, Nakanishi M. et al. Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells. J Exp Med. 2010;207(13):2817–2830. doi:10.1084/jem.20100844.
   PubMed Web of Science ®Google Scholar
• Takayama N, Nishikii H, Usui J, Tsukui H, Sawaguchi A, Hiroyama T, Eto K, Nakauchi H. Generation of functional platelets from human embryonic stem cells in vitro via ES-sacs, VEGF-promoted structures that concentrate hematopoietic progenitors. Blood. 2008;111(11):5298–5306. doi:10.1182/blood-2007-10-117622.
   PubMed Web of Science ®Google Scholar
• Choo SY. The HLA system: genetics, immunology, clinical testing, and clinical implications. Yonsei Med J. 2007;48(1):11–23. doi:10.3349/ymj.2007.48.1.11.
   PubMed Web of Science ®Google Scholar
• Suzuki D, Flahou C, Yoshikawa N, Stirblyte I, Hayashi Y, Sawaguchi A, Akasaka M, Nakamura S, Higashi N, Xu H. et al. iPSC-derived platelets depleted of HLA class I are inert to anti-HLA class I and natural killer cell immunity. Stem Cell Rep. 2020;14(1):49–59. doi:10.1016/j.stemcr.2019.11.011.
   PubMed Web of Science ®Google Scholar
• Norbnop P, Ingrungruanglert P, Israsena N, Suphapeetiporn K, Shotelersuk V. Generation and characterization of HLA-universal platelets derived from induced pluripotent stem cells. Sci Rep. 2020;10(1). doi:10.1038/s41598-020-65577-x.
   PubMed Web of Science ®Google Scholar
• Sim X, Poncz M, Gadue P, French DL. Understanding platelet generation from megakaryocytes: implications for in vitro-derived platelets. Blood. 2016;127(10):1227–33. doi:10.1182/blood-2015-08-607929.
   PubMed Web of Science ®Google Scholar
• Ito Y, Nakamura S, Sugimoto N, Shigemori T, Kato Y, Ohno M, Sakuma S, Ito K, Kumon H, Hirose H. et al. Turbulence activates platelet biogenesis to enable clinical scale ex vivo production. Cell. 2018;174(3):636. doi:10.1016/j.cell.2018.06.011.
   PubMed Web of Science ®Google Scholar
• Junt T, Schulze H, Chen Z, Massberg S, Goerge T, Krueger A, Wagner DD, Graf T, Italiano JE Jr., Shivdasani RA. et al. Dynamic visualization of thrombopoiesis within bone marrow. Sci. 2007;317(5845):1767–1770. doi:10.1126/science.1146304.
   PubMed Web of Science ®Google Scholar
• Sugimoto N, Kanda J, Nakamura S, Kitano T, Hishizawa M, Kondo T, Shimizu S, Shigemasa A, Hirai H, Arai Y. et al. iPLAT1: the first-in-human clinical trial of iPSC- derived platelets as a phase 1 autologous transfusion study. Blood. 2022;140(22):2398–2402. doi:10.1182/blood.2022017296.
   PubMed Web of Science ®Google Scholar
• Andrews PW, Barbaric I, Benvenisty N, Draper JS, Ludwig T, Merkle FT, Sato Y, Spits C, Stacey GN, Wang H. et al. The consequences of recurrent genetic and epigenetic variants in human pluripotent stem cells. Cell Stem Cell. 2022;29(12):1624–1636. doi:10.1016/j.stem.2022.11.006.
   PubMed Web of Science ®Google Scholar
• Merkle FT, Ghosh S, Kamitaki N, Mitchell J, Avior Y, Mello C, Kashin S, Mekhoubad S, Ilic D, Charlton M. et al. Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations. Nature. 2017;545(7653):229–233. doi:10.1038/nature22312.
   PubMed Web of Science ®Google Scholar
• Zhang XH, Tee LY, Wang XG, Huang QS, Yang SH. Off-target effects in CRISPR/Cas9-mediated genome engineering. Mol Ther Nucleic Acids. 2015;4:4. doi:10.1038/mtna.2015.37.
   Google Scholar
• Jackson AL, Linsley PS. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov. 2010;9(1):57–67. doi:10.1038/nrd3010.
   PubMed Web of Science ®Google Scholar
• Mockenhaupt S, Grosse S, Rupp D, Bartenschlager R, Grimm D. Alleviation of off-target effects from vector-encoded shRnas via codelivered RNA decoys. Proc Natl Acad Sci USA. 2015;112(30):4007–16. doi:10.1073/pnas.1510476112.
   PubMed Web of Science ®Google Scholar
• Ran FA, Hsu PD, Lin C-Y, Gootenberg JS, Konermann S, Trevino AE, Scott DA, Inoue A, Matoba S, Zhang Y. et al. Double nicking by RNA-Guided CRISPR Cas9 for enhanced genome editing specificity (vol 154, pg 1380, 2013). Cell. 2013;155(2):479–80. doi:10.1016/j.cell.2013.09.040.
   Web of Science ®Google Scholar
• Nemudryi AA, Valetdinova KR, Medvedev SP, Zakian SM. TALEN and CRISPR/Cas genome editing systems: tools of discovery. Acta Naturae. 2014;6(3):19–40. doi:10.32607/20758251-2014-6-3-19-40.
   PubMed Web of Science ®Google Scholar
• Yang RC, Zhou H, Hu Y, Yin J, Li JM, Chen WM, Huang RB, Gong YP, Luo CW, Liu XF. et al. Safety, pharmacokinetics and preliminary efficacy of HMPL-523 in adult patients with primary immune thrombocytopenia: a randomized, double-blind and placebo-controlled phase 1b study. Blood. 2021;138:16–16. doi:10.1182/blood-2021-149895.
   Web of Science ®Google Scholar
• Vo P, Purev E, West KA, McDuffee E, Worthy T, Cook L, Hawks G, Wells B, Shalabi R, Flegel WA. et al. A pilot trial of complement inhibition using eculizumab to overcome platelet transfusion refractoriness in human leukocyte antigen allo-immunized patients. Br J Haematol. 2020;189(3):551–558. doi:10.1111/bjh.16385.
   PubMed Web of Science ®Google Scholar
• Webber AM, Bradstreet TR, Wang X, Guo H, Nelson CA, Fremont DH, Edelson BT, Liu C. Antigen-guided depletion of anti-HLA antibody–producing cells by HLA-Fc fusion proteins. Blood. 2022;140:1803–15. doi:10.1182/blood.2022016376.
   PubMed Web of Science ®Google Scholar
• Ramsland PA, Farrugia W, Bradford TM, Sardjono CT, Esparon S, Trist HM, Powell MS, Tan PS, Cendron AC, Wines BD. et al. Structural basis for Fc gammaRiia recognition of human IgG and formation of inflammatory signaling complexes. J Immunol. 2011;187(6):3208–17. doi:10.4049/jimmunol.1101467.
   PubMed Web of Science ®Google Scholar
• Kizlik-Masson C, Deveuve Q, Zhou Y, Vayne C, Thibault G, McKenzie SE, Pouplard C, Loyau S, Gruel Y, Rollin J. Cleavage of anti-PF4/heparin IgG by a bacterial protease and potential benefit in heparin-induced thrombocytopenia. Blood. 2019;133(22):2427–2435. doi:10.1182/blood.2019000437.
   PubMed Web of Science ®Google Scholar
• Lynch DR, Stringham EN, Zhang B, Balbin-Cuesta G, Curtis BR, Palumbo JS, Greineder CF, Tourdot BE. Anchoring IgG-degrading enzymes to the surface of platelets selectively neutralizes antiplatelet antibodies. Blood Adv. 2022;6(15):4645–56. doi:10.1182/bloodadvances.2022007195.
   PubMed Web of Science ®Google Scholar